On the other hand, there is currently no conclusive evidence supporting the benefit of TP53 mutation clearance prior to transplantation in patients with TP53-mutated AML, and further investigation is needed to clarify this issue [39,44]. This evidence concerns the gene TP53 and acute myeloid leukemia.